Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review

Borgeaud, Maxime; Parikh, Kaushal; Banna, Giuseppe Luigi; Kim, Floryane; Olivier, Timothée; Le, Xiuning; Addeo, Alfredo

doi:10.1016/j.jtho.2024.03.016

Journal of Thoracic Oncology

2024

DOI: 10.1016/j.jtho.2024.03.016

|View full text |Cite

Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review

Maxime Borgeaud,

Kaushal Parikh,

Giuseppe Luigi Banna

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01

Hibino,

Imamura,

Shimoyama

et al. 2024

Targ Oncol

View full text Add to dashboard Cite

Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01

Hibino,

Imamura,

Shimoyama

et al. 2024

Targ Oncol

View full text Add to dashboard Cite

Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer

Gray,

Mutti,

Meirson

2024

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response

Anghel,

Dinu-Pirvu,

Costache

et al. 2024

IJMS

View full text Add to dashboard Cite

The paradigm “one drug fits all” or “one dose fits all” will soon be challenged by pharmacogenetics research and application. Drug response—efficacy or safety—depends on interindividual variability. The current clinical practice does not include genetic screening as a routine procedure and does not account for genetic variation. Patients with the same illness receive the same treatment, yielding different responses. Integrating pharmacogenomics in therapy would provide critical information about how a patient will respond to a certain drug. Worldwide, great efforts are being made to achieve a personalized therapy-based approach. Nevertheless, a global harmonized guideline is still needed. Plasma membrane proteins, like receptor tyrosine kinase (RTK) and G protein-coupled receptors (GPCRs), are ubiquitously expressed, being involved in a diverse array of physiopathological processes. Over 30% of drugs approved by the FDA target GPCRs, reflecting the importance of assessing the genetic variability among individuals who are treated with these drugs. Pharmacogenomics of transmembrane protein receptors is a dynamic field with profound implications for precision medicine. Understanding genetic variations in these receptors provides a framework for optimizing drug therapies, minimizing adverse reactions, and advancing the paradigm of personalized healthcare.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review

Cited by 3 publications

References 52 publications

Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01

Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01

Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer

Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response

Contact Info

Product

Resources

About